PB2328: TRIAL IN PROGRESS: ATHENA-1 – A PHASE 1 STUDY TO ASSESS SAFETY AND TOLERABILITY OF REGN5837 IN COMBINATION WITH ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA

• Pim G. N. J. Mutsaers,
• Jeremy S. Abramson,
• Manjusha Namuduri,
• Jingjin LI,
• Nickolas A. Sophos,
• Min Zhu,
• Jurriaan Brouwer-Visser,
• Hesham Mohamed,
• Aafia Chaudhry,
• Andrew J. Davies

Affiliations

Pim G. N. J. Mutsaers

1 Erasmus University Medical Center, Rotterdam, The Netherlands

Jeremy S. Abramson

2 Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States

Manjusha Namuduri

3 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States

Jingjin LI

3 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States

Nickolas A. Sophos

3 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States

Min Zhu

3 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States

Jurriaan Brouwer-Visser

3 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States

Hesham Mohamed

3 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States

Aafia Chaudhry

3 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States

Andrew J. Davies

4 Southampton NIHR/Cancer Research UK Experimental Cancer Medicines Centre, University of Southampton, Southampton, United Kingdom